Deutsche Bank AG Increases Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Deutsche Bank AG grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 54.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 142,869 shares of the biotechnology company's stock after purchasing an additional 50,575 shares during the period. Deutsche Bank AG owned approximately 0.10% of Aurinia Pharmaceuticals worth $1,283,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. SBI Securities Co. Ltd. purchased a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC increased its position in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 2,635 shares during the last quarter. Natixis purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at $49,000. Blue Trust Inc. lifted its stake in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 6,174 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at about $90,000. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock traded down $0.12 during midday trading on Friday, reaching $7.88. 163,839 shares of the company were exchanged, compared to its average volume of 1,331,362. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -52.50 and a beta of 1.16. The firm's 50-day simple moving average is $7.99 and its 200-day simple moving average is $8.27. Aurinia Pharmaceuticals Inc. has a 1 year low of $5.15 and a 1 year high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The company had revenue of $62.47 million during the quarter, compared to analysts' expectations of $61.06 million. On average, analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.

Insider Activity

In related news, CEO Peter Greenleaf sold 195,593 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the transaction, the chief executive officer now directly owns 1,953,892 shares of the company's stock, valued at approximately $15,631,136. This represents a 9.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $527,216.00. Following the sale, the chief operating officer now directly owns 739,456 shares in the company, valued at $5,915,648. This represents a 8.18% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 343,898 shares of company stock worth $2,753,094. Company insiders own 12.20% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.